Solaris Vaccines, Inc.
Fort Collins, CO
- UEI
- G1P5NEDCERA9
- CAGE
- 97FY7
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 3185 Rampart Rd, Fort Collins, CO 80521, USA
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $0 |
| FY2025 | $1,298,431 |
| FY2024 | $249,723 |
Contract awards
Grant awards
Similar vendors
About the company
Solaris Vaccines, Inc. is a small, for-profit biotechnology company located in Fort Collins, Colorado, specializing in innovative vaccine development and inactivation technologies. The company focuses on creating advanced vaccine solutions using a unique photosensitizer (riboflavin) and ultraviolet light method to disrupt pathogen genetic material while preserving antigenic integrity. Through federal contract and grant awards, Solaris Vaccines demonstrates expertise in developing cutting-edge vaccine technologies across multiple infectious disease domains, with a particular emphasis on creating whole-cell inactivated vaccines using advanced scientific approaches.
In terms of federal contract awards, Solaris Vaccines, Inc. has secured Small Business Innovation Research (SBIR) contracts with the Defense Health Agency (DHA). These contracts are specifically focused on developing the "VacciraRptor" technology, a high-throughput, continuous flow-through system for psoralen-UVA inactivation. The company has been awarded two contracts totaling approximately $1.5 million, with the most recent Phase II contract valued at $1,298,431.22 and a performance period extending through November 1, 2027. Both contracts were total small business set-asides, reflecting the company's status as a small business and its innovative research capabilities in vaccine development technologies.
Regarding federal grant awards, Solaris Vaccines, Inc. has received project grants from the National Institute of Allergy and Infectious Diseases (NIAID) focusing on advanced vaccine research. The grants include a $269,874 two-year project to develop SOLAVAX-TB, a whole-cell inactivated Mycobacterium tuberculosis vaccine aimed at improving protection against tuberculosis, with a performance period from August 1, 2025 to July 31, 2027. Another grant focused on developing improved influenza vaccine production methods using their novel Solavax inactivation technology. These grants demonstrate the company's commitment to addressing critical infectious disease challenges through innovative vaccine research, with a particular emphasis on developing more effective, adaptable, and comprehensive vaccine solutions for global health threats.
Quick answers
Is Solaris Vaccines, Inc. registered in SAM.gov?
Yes. Solaris Vaccines, Inc.'s SAM.gov registration is active through April 28, 2027.
How much has Solaris Vaccines, Inc. received in federal contracts?
Federal contracts obligated $1,298,431 to Solaris Vaccines, Inc. in fiscal year 2025 and $1,548,155 in fiscal years 2023 through 2027.
What is Solaris Vaccines, Inc.'s most recent federal award?
Solaris Vaccines, Inc.'s most recent federal grant award is A whole-cell inactivated vaccine for improved protection against tuberculosis (R41AI186746), from National Institute of Allergy and Infectious Diseases (NIH), on August 1, 2025.
On GovTribe
See Solaris Vaccines, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors